Title: Eribulin synergizes with Polo-like kinase 1 inhibitors to induce apoptosis in rhabdomyosarcoma.
Journal: Cancer letters 20150828
Title: Centmitor-1, a novel acridinyl-acetohydrazide, possesses similar molecular interaction field and antimitotic cellular phenotype as rigosertib, on 01910.Na.
Journal: Molecular cancer therapeutics 20140501
Title: Dual kinase-bromodomain inhibitors for rationally designed polypharmacology.
Journal: Nature chemical biology 20140401
Title: BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1.
Journal: Cancer medicine 20131201
Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.
Journal: Bioorganic & medicinal chemistry letters 20130801
Title: Hit to Lead optimization of a novel class of squarate-containing polo-like kinases inhibitors.
Journal: Bioorganic & medicinal chemistry letters 20121215
Title: Enabling and disabling polo-like kinase 1 inhibition through chemical genetics.
Journal: ACS chemical biology 20120615
Title: Using transcriptome sequencing to identify mechanisms of drug action and resistance.
Journal: Nature chemical biology 20120301
Title: Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells.
Journal: Breast cancer research : BCR 20120101
Title: Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells.
Journal: BMC cancer 20120101
Title: Comprehensive analysis of kinase inhibitor selectivity.
Journal: Nature biotechnology 20111030
Title: Formation of stable attachments between kinetochores and microtubules depends on the B56-PP2A phosphatase.
Journal: Nature cell biology 20111001
Title: Polo-like kinase 1 inhibition as a new therapeutic modality in therapy of cholangiocarcinoma.
Journal: Anticancer research 20111001
Title: Phosphorylation of Ataxin-10 by polo-like kinase 1 is required for cytokinesis.
Journal: Cell cycle (Georgetown, Tex.) 20110901
Title: Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536.
Journal: Haematologica 20110501
Title: Small molecule kinase inhibitor screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-initiating cells.
Journal: Cancer research 20110215
Title: Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translation.
Journal: PloS one 20110101
Title: Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.
Journal: Chemistry & biology 20101124
Title: Prediction of neutropenia-related effects of a new combination therapy with the anticancer drugs BI 2536 (a Plk1 inhibitor) and pemetrexed.
Journal: Clinical pharmacology and therapeutics 20101101
Title: Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
Journal: Cancer research 20100215
Title: Treatment of biliary tract cancer with NVP-AEW541: mechanisms of action and resistance.
Journal: World journal of gastroenterology 20100114
Title: The Plk1 inhibitor BI 2536 temporarily arrests primary cardiac fibroblasts in mitosis and generates aneuploidy in vitro.
Journal: PloS one 20100101
Title: PLK1 down-regulates parainfluenza virus 5 gene expression.
Journal: PLoS pathogens 20090701
Title: Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology.
Journal: The oncologist 20090601
Title: Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma.
Journal: Cancer research 20090301
Title: Selectivity-determining residues in Plk1.
Journal: Chemical biology & drug design 20071201
Title: Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity.
Journal: Biochemistry 20070821
Title: BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.
Journal: Current biology : CB 20070220
Title: Lénárt P, et al. The Small-Molecule Inhibitor BI 2536 Reveals Novel Insights into Mitotic Roles of Polo-like Kinase 1. Curr Biol. 2007 Feb 20;17(4):304-15.
Title: Chen L, et al. BRD4 Structure-Activity Relationships of Dual PLK1 Kinase/BRD4 Bromodomain Inhibitor BI-2536. ACS Med Chem Lett. 2015 May 18;6(7):764-9.
Title: Steegmaier M, et al. BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo. Current Biology (2007), 17(4), 316-322.
Title: Malik N, et al. Suppression of IFN β gene transcription by inhibitors of bromodomain and extra-terminal (BET) family members. Biochem J. 2015 Jun 15;468(3):363-72.
